Compare Amylx Pharmaceuticals Inc (AMLX) vs Yum China Holdings Inc (YUMC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Yum China Holdings Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Yum China Holdings Inc trades at $43.99 (market cap $14.80B). The key difference: Yum China Holdings Inc is far larger — about 7.5× Amylx Pharmaceuticals Inc's market cap, and Yum China Holdings Inc pays a 2.7% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | YUMC | |
|---|---|---|
Market Cap | $1.98B | $14.80B |
Sector | Health | Consumer Cyclical |
52-Week High | $18.70 | $57.95 |
52-Week Low | $7.64 | $40.18 |
Enterprise Value | $1.70B | $15.69B |
Dividend Yield | — | 2.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
YUMC trades at $43.02, up 1.68% today, with a neutral technical signal and strong fundamentals including consistent earnings beats. Revenue grew to $11.80B in 2025, with a net margin of 7.83%. The company recently announced a $0.29 dividend and a $512M share repurchase, while acquiring full ownership of Pizza Hut in mainland China, signaling strategic expansion.
Outlook remains positive with analyst consensus at 74% buy ratings, though risks include China's competitive dining market and currency volatility. The stock's P/E of 16.48 and ROE of 16.87% support value, but investors should monitor Q2 2026 earnings due July 30, 2026, for growth sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Yum China Holdings Inc
With almost 10,600 units and USD 9.5 billion in systemwide sales in 2020, Yum China is the largest restaurant chain in China. It generates revenue through its own restaurants and franchise fees. Key concepts include KFC (7,166 units) and Pizza Hut (2,355), but the company's portfolio also includes other brands such as Little Sheep, East Dawning, Taco Bell, Huang Ji Huang, COFFii & Joy, and Lavazza (collectively representing about 985 units). Yum China is a trademark licensee of Yum Brands, paying 3% of total systemwide sales to the company it separated from in October 2016.
Read more on YUMC →
